36 related articles for article (PubMed ID: 30667391)
1. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib.
Casadei-Gardini A; Dadduzio V; Rovesti G; Cabibbo G; Vukotic R; Rizzato MD; Orsi G; Rossi M; Guarneri V; Lonardi S; D'agostino D; Celsa C; Andreone P; Zagonel V; Scartozzi M; Cascinu S; Cucchetti A
Medicine (Baltimore); 2020 May; 99(22):e19958. PubMed ID: 32481366
[TBL] [Abstract][Full Text] [Related]
2. Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis.
Nishikawa H; Enomoto H; Yoh K; Iwata Y; Sakai Y; Kishino K; Shimono Y; Ikeda N; Takashima T; Aizawa N; Takata R; Hasegawa K; Ishii N; Yuri Y; Nishimura T; Iijima H; Nishiguchi S
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121095
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?
Cabibbo G; Rossi M; Celsa C; Maida M; Cammà C
Recenti Prog Med; 2018 Dec; 109(12):605-608. PubMed ID: 30667391
[TBL] [Abstract][Full Text] [Related]
5. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence.
Celsa C; Stornello C; Giuffrida P; Giacchetto CM; Grova M; Rancatore G; Pitrone C; Di Marco V; Cammà C; Cabibbo G
Ann Hepatol; 2022 Jan; 27 Suppl 1():100568. PubMed ID: 34699987
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.
Galati G; Muley M; Viganò M; Iavarone M; Vitale A; Dell'Unto C; Lai Q; Cabibbo G; Sacco R; Villa E; Trevisani F
Expert Opin Drug Saf; 2019 Jul; 18(7):603-610. PubMed ID: 31067134
[TBL] [Abstract][Full Text] [Related]
7. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
